| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Anesthesiology and Neurology, University of Washington School of Medicine, Seattle, WA.
Address correspondence and reprint requests to Dr. Bradley S. Galer, Multidisciplinary Pain Center, University of Washington Medical Center-Roossevelt, Box 354750, 4245 Roosevelt Way, NE, Seattle, WA 98105.
A variety of mechanisms may generate pain resulting from injury to the peripheral nervous system.None of these mechanisms is disease-specific, and several different pain mechanisms may be simultaneously present in any one patient, independent of diagnosis. Diagnosis of neuropathic pain is often easily made from information gathered on neurologic examination and from patient history. Evidence of sensory disturbances elicited on examination combined with laboratory tests confirming injury to peripheral nerve establishes the diagnosis of neuropathic pain. Although treatment of neuropathic pain may be difficult, optimum treatment can be achieved if the neurologist has a complete understanding of the therapeutic options, the mainstay of which is pharmacotherapy. Selection of an appropriate pharmacologic agent is by trial and error since individual responses to different agents, doses, and serum levels are highly variable. An adequate trial for each agent tried is key to pharmacologic treatment of neuropathic pain. Tricyclic antidepressants are first-line agents, although other drugs, including anticonvulsants, local anesthetic antiarrhythmics, clonidine, opioids, and certain topical agents, also offer pain relief in some patient populations. The novel antidepressants venlafaxine and nefazodone are potentially useful new drugs that are better tolerated than tricyclic antidepressants.
NEUROLOGY 1995;45(suppl 9): S17-S25
This article has been cited by other articles:
|
|
 |
|
  M. Rogers, A. Rasheed, A. Moradimehr, and S. J. Baumrucker Memantine (Namenda) for Neuropathic Pain American Journal of Hospice and Palliative Medicine, February 1, 2009; 26(1): 57 - 59. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Vissers and T. Meert A Behavioral and Pharmacological Validation of the Acetone Spray Test in Gerbils with a Chronic Constriction Injury Anesth. Analg., August 1, 2005; 101(2): 457 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. HAZARI and D. ELLIOT Treatment of End-Neuromas, Neuromas-in-Continuity and Scarred Nerves of the Digits by Proximal Relocation J Hand Surg Eur Vol., August 1, 2004; 29(4): 338 - 350. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Field, M. I. Gonzalez, R. J. Tallarida, and L. Singh Gabapentin and the Neurokinin1 Receptor Antagonist CI-1021 Act Synergistically in Two Rat Models of Neuropathic Pain J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 730 - 735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Abresch, G. T. Carter, M. P. Jensen, and D. D. Kilmer Assessment of pain and health-related quality of life in slowly progressive neuromuscular disease American Journal of Hospice and Palliative Medicine, January 1, 2002; 19(1): 39 - 48. [Abstract] [PDF]
|
|
|
|
 |
|
 M. R. Semenchuk, S. Sherman, and B. Davis Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain Neurology, November 13, 2001; 57(9): 1583 - 1588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Drug treatment of neuropathic pain DTB, December 1, 2000; 38(12): 89 - 93. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. PADILLA, G. T. CLARK, and R. L. MERRILL TOPICAL MEDICATIONS FOR OROFACIAL NEUROPATHIC PAIN: A REVIEW J Am Dent Assoc, February 1, 2000; 131(2): 184 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Donovan and K. D. Laack Individually Reported Effectiveness of Therapy for Chronic Pain Clin Nurs Res, November 1, 1998; 7(4): 423 - 439. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
